• Mechanism

    SMAC mimetic (Intravenous)

  • Disease areas

    Solid tumors

Birinapant - for the treatment of solid tumors

Birinapant is a SMAC mimetic that was acquired from TetraLogic Pharmaceuticals Corporation (TetraLogic) in 2016 and has since then been developed by Medivir for the treatment of solid tumors. Birinapant has the potential, in combination with other pharmaceuticals, to improve treatment response and prolong survival among patients with solid tumors for whom available treatments provide insufficient survival, or for patients who no longer have any treatment options.



IGM Biosciences Inc.


Project status and Medivir participation

In January 2021 Medivir entered into an exclusive licensing agreement, through which IGM Biosciences Inc., will receive global, exclusive development rights for birinapant.

Medivir received a payment of USD 1 million upon signing the agreement, which was followed by an additional USD 1.5 million when IGM in November 2021 initiated a clinical phase I study in solid cancers with birinapant in combination with its DR5-agonist antibody IGM-8444. As of Q1 2023, IGM reported that the fourth dose-escalation cohort was completed, and no dose-limiting toxicities has been observed to date. IGM has started the dosing of a fifth cohort in the study.

The terms of the agreement entitles Medivir to milestone payments up to a total of approximately USD 350 million, given that birinapant is successfully developed and approved, and tiered royalties up to "mid-teens” on net sales. A portion of all revenue is shared with Tetralogic Pharmaceuticals Corporation, but the main part goes to Medivir.

Presentation held at the announcement of the licensing agreement.

Projects from our team

Fostroxacitabine bralpamide (fostrox)

Nucleotide DNA polymerase inhibitor (oral)


HDAC inhibitor (topical)


Cathepsin K inhibitor (oral)